VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer

VEGF inhibitors: a new era in the treatment of metastatic ovarian cancer

O affect angiogenesis is one of the key goals of therapy for ovarian cancer (OC). The advent of targeted drugs that selectively affect neoangiogenesis has been a breakthrough in treating OC in the past decade. By now the only drug validly demonstrating antiangiogenic activity is bevacizumab whose ef...

Full description

Bibliographic Details
Main Author:	S Pignata
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2013-06-01
Series:	Современная онкология
Subjects:	ovarian cancer vascular endothelial growth factor targeted inhibition of angiogenesis bevacizumab
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26901

Similar Items

Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
by: Ioannis Kapelakis, et al.
Published: (2017-05-01)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
by: Maria Kaparelou, et al.
Published: (2022-04-01)

Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature
by: Lawrence Kasherman, et al.
Published: (2021-01-01)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
by: Chih-Lin Mao, et al.
Published: (2022-06-01)

Angiogenesis Inhibitors in Small Cell Lung Cancer
by: Agnese Montanino, et al.
Published: (2021-05-01)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
by: Roberto Ria, et al.
Published: (2020-06-01)

The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas
by: Luiz Victor Maia Loureiro, et al.
Published: (2020-03-01)

Can angiogenesis inhibitor therapy cause changes in imaging features of hepatic hemangioma- Initial study
by: Tang Liu, et al.
Published: (2023-03-01)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
by: Muñoz-Villegas P, et al.
Published: (2021-05-01)

Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption
by: James L. Rubenstein, et al.
Published: (2000-07-01)

Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis
by: Xu M, et al.
Published: (2022-09-01)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
by: Ju Yang, et al.
Published: (2018-05-01)

The effects of anti-VEGF drugs on the retinal pigment epithelium and inner segment after intravitreal injection in the monkeys
by: Nan Su, et al.
Published: (2016-06-01)

Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer
by: Yachana Mishra, et al.
Published: (2023-06-01)

The role of angiogenesis blockers in the treatment of metastatic ovarian cancer
by: M R Oganian, et al.
Published: (2013-12-01)

VEGF111: new insights in tissue invasion
by: Kevin eDanastas, et al.
Published: (2015-01-01)

Inhibitor of differentiation-1 promotes angiogenesis of human osteosarcoma by regulating VEGF-A
by: ZHAO Guosheng, et al.
Published: (2021-05-01)

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
by: Klaudia Żak, et al.
Published: (2024-03-01)

Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease
by: Min Zhang, et al.
Published: (2024-01-01)

Prognostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients
by: Oana Gabriela Trifanescu, et al.
Published: (2023-01-01)

Book Review: Anti-VEGF Use in Ophthalmology
by: Robin A. Vora
Published: (2017-09-01)

Anti VEGF for post op CME- Boon or Bane!
by: Roshni Mohan, et al.
Published: (2022-01-01)

Administration of Bevacizumab and the Risk of Chronic Kidney Disease Development in Taiwan Residents: A Population-Based Retrospective Cohort Study
by: Lon-Fye Lye, et al.
Published: (2023-12-01)

Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors
by: Rodrigo Barbosa de Aguiar, et al.
Published: (2019-05-01)

A new rat model of treatment-naive quiescent choroidal neovascularization induced by human VEGF165 overexpression
by: Shan Liu, et al.
Published: (2020-06-01)

Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
by: Patrick R. Merz, et al.
Published: (2018-12-01)

Deregulation of angiopoietin-like 4 slows ovarian cancer progression through vascular endothelial growth factor receptor 2 phosphorylation
by: Yuxian Wu, et al.
Published: (2021-03-01)

The outcome of Concurrent Diode Laser Cyclophotocoagulation and Bevacizumab for Treatment of Neovascular Glaucoma
by: Riad Elzaher Hassan Ahmed, et al.
Published: (2022-03-01)

Comparison of the effect of intravitreal bevacizumab and intravitreal fasudil on retinal VEGF, TNFα, and caspase 3 levels in an experimental diabetes model
by: Fatih Çelik, et al.
Published: (2014-02-01)

Activation of TF-Dependent Blood Coagulation Pathway and VEGF-A in Patients with Essential Thrombocythemia
by: Grażyna Gadomska, et al.
Published: (2019-02-01)

Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab
by: Jiu-Ke Li, et al.
Published: (2015-12-01)

Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels
by: Meiling Zhang, et al.
Published: (2023-12-01)

In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
by: Mohammad Hosseininejad-Chafi, et al.
Published: (2022-01-01)

Expression of VEGF165 and VEGF165b during ovarian follicular development
by: Chinnarat Changsangfa, et al.
Published: (2023-01-01)

Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
by: Makoto Hibino, MD, et al.
Published: (2022-12-01)

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
by: Sun Weijing
Published: (2012-10-01)

Inflammatory Complications of Intravitreal Anti-VEGF Injections
by: Jacob T. Cox, et al.
Published: (2021-03-01)

Serum levels of VEGF-A, sVEGFR-2 and galectin-3 do not correlate with clinical stage, tumor size, or effectiveness of perioperative chemotherapy in patients with non-metastatic breast cancer
by: Iga Grochoła-Małecka, et al.
Published: (2022-09-01)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
by: Maria Waizel, et al.
Published: (2017-05-01)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018-08-01)